---
title: "Argo Biopharma to present at 44th J.P. Morgan Healthcare Conference on Jan. 11, 2026 in Shanghai and Boston. Dr. Shu to speak."
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/272194647.md"
description: "On January 11, 2026, Argo Biopharmaceutical Co., Ltd. revealed from Shanghai and Boston its plans for advancing siRNA therapies, with Dr. Dongxu Shu, a Co-Founder, Chairman of the Board, and CEO, leading the efforts. Argo Biopharma is a clinical-stage biotechnology company dedicated to developing innovative siRNA treatments for various conditions."
datetime: "2026-01-12T00:03:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272194647.md)
  - [en](https://longbridge.com/en/news/272194647.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272194647.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/272194647.md) | [繁體中文](https://longbridge.com/zh-HK/news/272194647.md)


# Argo Biopharma to present at 44th J.P. Morgan Healthcare Conference on Jan. 11, 2026 in Shanghai and Boston. Dr. Shu to speak.

On January 11, 2026, Argo Biopharmaceutical Co., Ltd. revealed from Shanghai and Boston its plans for advancing siRNA therapies, with Dr. Dongxu Shu, a Co-Founder, Chairman of the Board, and CEO, leading the efforts. Argo Biopharma is a clinical-stage biotechnology company dedicated to developing innovative siRNA treatments for various conditions.

## 相关资讯与研究

- [Shanghai Fudan-Zhangjiang Bio-Pharmaceutical subscribes to structured deposit product under Bank of China](https://longbridge.com/zh-CN/news/281521127.md)
- [Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton | IMUX Stock News](https://longbridge.com/zh-CN/news/281169480.md)
- [08:27 ETinThought Announces the Promotion of Dr. Amanda Weyerbacher to Executive VP](https://longbridge.com/zh-CN/news/281186594.md)
- [Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call](https://longbridge.com/zh-CN/news/281187029.md)
- [Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 | SRPT Stock News](https://longbridge.com/zh-CN/news/280468934.md)